FDA won't review Afrezza until July

MannKind is going to have to wait a little longer to find out its regulatory fate: the FDA has pushed off its review decision of the inhaled insulin Afrezza for another three months.

The company said in a statement on Monday that the FDA wants more time to review the application. Barron's reports that this is not a surprise for Cowen analysts Simos Simeonidis and Yatin Suneja, both of whom expect the regulator to approve the diabetes medication “in great part because of what is viewed as a ‘real need' for specific patient groups,” they said.

An FDA advisory panel endorsed the drug last week, surprising many, both because of the drug assessments posted online before the panel convened, and the fact that the FDA had already rejected the drug three times.

You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.